A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms CONTINUATION
- Sponsors Baxalta; Baxter International; Shire
- 27 Oct 2020 According to a Takeda media release, data from this study will be presented at the Thrombosis and Hemostasis Summit of North America (THSNA) 2020.
- 12 Jul 2020 According to a Takeda media release, data from this study will be presented at the International Society on Thrombosis and Haemostasis 2020 Virtual Congress (ISTH 2020).
- 05 Feb 2020 According to a Takeda media release, pooled data from this and other five trials (NCT01599819, NCT01736475, NCT01913405, NCT02210091, NCT02585960) is being presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020.